| Related Articles |
Comparative Efficacy and Safety of New Oral Anticoagulants in Patients With Atrial Fibrillation.
Circ Cardiovasc Qual Outcomes. 2012 Jul 10;
Authors: Schneeweiss S, Gagne JJ, Patrick AR, Choudhry NK, Avorn J
Abstract
BACKGROUND: score ?3. We found no statistically significant efficacy differences among the 3 drugs, although apixaban and dabigatran were numerically superior to rivaroxaban. Apixaban produced significantly fewer major hemorrhages than dabigatran and rivaroxaban. CONCLUSIONS: score ?3 dabigatran 150 mg, apixaban 5 mg, and rivaroxaban 20 mg resulted in statistically similar rates of stroke and systemic embolism, but apixaban had a lower risk of major hemorrhage compared with dabigatran and rivaroxaban. Until head-to-head trials or large-scale observational studies that reflect routine use of these agents are available, such adjusted indirect comparisons based on trial data are one tool to guide initial therapeutic choices.
PMID: 22787066 [PubMed - as supplied by publisher]